Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Says USPTO Reverses Rejection of US Patent


Australia's Benitec said this week that the US Patent and Trademark Office has reversed its previous rejections of claims within the company's core US patent.

The patent, No. 6,573,099, covers gene-expression knockdown using DNA that transcribes double-stranded RNA. It fell under USPTO scrutiny as part of patent-infringement litigation the company initiated against now-defunct expressed RNAi shop Nucleonics, and certain claims within the intellectual property were rejected by the patent office (see GSN, 1/21/2010).

However, Benitec said that the rejection of all appealed claims in the patent has been reversed.

"It is therefore anticipated that the USPTO will soon issue a notice of intent to issue [an] ex parte re-examination certificate … which is analogous to the re-issuance of the patent certificate," the company said. "This notice would formally terminate the re-examination proceeding."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.